Enrolling By Invitation PHASE2 INTERVENTIONAL 1-arm NCT06931613

Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment

Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment With or Without Bendamustine

Sponsor: St. Petersburg State Pavlov Medical University

Conditions Autologous Haemopoietic Stem Cell Transplant Children Nivolumab Relapsed or Refractory Hodgkin Lymphoma

Interventions Nivolumab

Updated 2 times since 2025 Last updated: Apr 9, 2025 Started: Jun 1, 2022 Primary completion: Jun 1, 2026 Completion: Jun 1, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06931613, this PHASE2 trial focuses on Autologous Haemopoietic Stem Cell Transplant and Children and remains ongoing. Sponsored by St. Petersburg State Pavlov Medical University, it has been updated 2 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

2 versions recorded

Sep 2025 — Present [monthly]

Enrolling By Invitation PHASE2
May 2025 — Sep 2025 [monthly]

Enrolling By Invitation PHASE2

First recorded

Jun 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

St. Petersburg State Pavlov Medical University

Data source: St. Petersburg State Pavlov Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Moscow, Russia
• Saint Petersburg, Russia